Original Article

Validation of Estimated Glomerular Filtration Slope and Proteinuria Reduction as

Surrogate Endpoints in IgA Nephropathy: A post-hoc Analysis from the J-IGACS

Takaya Sasaki[1], Nobuo Tsuboi[1*], Kentaro Koike[1], Hiroyuki Ueda[1], Masahiro Okabe[1], Shinya

Yokote[1], Akihiro Shimizu[1], Keita Hirano[1], Tetsuya Kawamura[1], Takashi Yokoo[1], Yusuke

Suzuki and the J-IGACS working group.

[1]Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei

University School of Medicine, Tokyo, Japan, [2]Department of Nephrology, Juntendo

University Faculty of Medicine, Tokyo, Japan.

Running title: Corticosteroid-Based Analysis of Surrogate Endpoints in IgA Nephropathy

*Correspondence to: Nobuo Tsuboi, M.D., Ph.D.

Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei

University School of Medicine, 3-25-8 Nishi-Shimbashi, Minato-ku, Tokyo, Japan

Tel: 81-3-3433-1111, Fax: 81-3-3433-4297, E-mail: tsuboi-n@jikei.ac.jp

Keywords: IgA nephropathy, proteinuria, eGFR slope, kidney outcome, corticosteroid

Abstract

Background: Estimated glomerular filtration rate (eGFR) slope and proteinuria reduction

have been proposed as surrogate endpoints for kidney outcomes in IgA nephropathy (IgAN),

but their validity remains under debate. We aimed to evaluate the surrogate potential of these

markers in the context of corticosteroid therapy within a large Japanese cohort.

Methods: Patients with biopsy-proven IgAN from the Japan IgA Nephropathy Cohort Study

(J-IGACS) were analyzed. Patients were categorized based on corticosteroid exposure within

12 months of diagnosis. To minimize confounding, overlap weighting was used to balance

baseline characteristics. The primary outcome was a composite kidney endpoint defined as a

≥40 decline in eGFR or the initiation of kidney replacement therapy. Secondary outcomes

included 2-year eGFR slope and proteinuria ratio at 1-year.

Results: Corticosteroid therapy was associated with a lower incidence of the composite

kidney outcome (15.5 vs. 28.2%, P = 0.007), slower decline in eGFR (-0.30 vs. -2.99

mL/min/1.73 m²/year, P = 0.001), and lower proteinuria ratio (0.521 vs. 0.235, P < 0.001).

These associations were consistent with predictions from established meta-regression models

that linked changes in surrogate markers to kidney outcomes across diverse kidney diseases

including IgAN.

Conclusion: Both the eGFR slope and proteinuria ratio demonstrated strong and consistent

associations with kidney outcomes in the context of corticosteroid therapy. These findings

support their validity as surrogate endpoints for clinical trials and suggest their usefulness for

risk stratification and therapeutic monitoring in routine nephrology practice.

Lay-Summary

IgA nephropathy (IgAN) is a common kidney disease that can lead to kidney failure over

time. To monitor treatment effectiveness, researchers often use early indicators like how

quickly kidney function declines (eGFR slope) and changes in protein levels in urine

(proteinuria). However, whether these markers truly reflect long-term outcomes remains

uncertain. In this study, we analyzed over 1,000 patients with biopsy-confirmed IgAN from a

nationwide Japanese cohort. We compared those who received corticosteroid treatment

within a year of diagnosis to those who did not. After adjusting for differences between

groups, we found that corticosteroid use was linked to better kidney outcomes, slower decline

in kidney function, and reduced proteinuria. These results matched predictions from

large-scale international studies. Our findings support the use of eGFR slope and proteinuria

as reliable surrogate endpoints in clinical trials and everyday care, helping doctors assess

treatment response more quickly and accurately.

Introduction

IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis globally

and a major cause of chronic kidney disease (CKD) and kidney failure [1, 2]. Because IgAN

progresses slowly over many years [3-5], establishing reliable surrogate endpoints that can be

evaluated over a short period is crucial for improving the efficiency of clinical trials and

guiding personalized treatment strategies as new therapies emerge. Among candidate

surrogate markers, the trajectory of the estimated glomerular filtration rate (eGFR) slope and

reduction in proteinuria have been proposed [6-9]. However, their validity remains a topic of

active discussion, particularly when applied to therapeutic interventions.

Corticosteroid therapy has long been a cornerstone of treatment for IgAN,

particularly in patients with persistent proteinuria despite supportive care. Importantly,

randomized controlled trials [10] and meta-analysis [11] studies have consistently

demonstrated that corticosteroids significantly reduce proteinuria and slow disease

progression, establishing their efficacy as a key therapeutic option. In Japan, in particular,

corticosteroid therapy has become widely adopted as a standard treatment in routine clinical

practice [12].

Previous meta-regression analyses across various CKDs, including IgAN, have

suggested that treatment-induced improvements in eGFR slope and reductions in proteinuria

are associated with favorable kidney outcomes [9, 13-15]. Nevertheless, extrapolation of

these findings to IgAN, especially in real-world cohorts with heterogeneous treatment

responses, requires careful evaluation. To address these gaps, we leveraged data from the

Japan IgA Nephropathy Cohort Study (J-IGACS) [12, 16] and focused on corticosteroid

therapy as a representative treatment intervention. Using overlap weighting to emulate

randomization and balance baseline characteristics, we examined whether corticosteroid

exposure was associated with improvements in eGFR slope, reduction in proteinuria, and

attenuation of kidney disease progression. In addition, we evaluated the consistency between

observed treatment effects and predictions derived from established meta-regression models

[9, 14, 15]. Through this approach, we aimed to validate eGFR slope and proteinuria

reduction as robust surrogate endpoints for kidney outcomes in IgAN, with particular

emphasis on their applicability in clinical trials and real-world practice.

Methods

Study Design and Population

This study is a post hoc analysis derived from the Japan IgA Nephropathy Cohort Study

(J-IGACS), a prospective, multicenter registry enrolling individuals with biopsy-proven

primary IgAN from April 1, 2005, to August 31, 2015 [12, 16]. Among the inclusion criteria

for the original J-IGACS study was a diagnostic kidney biopsy containing a minimum of 10

glomeruli, a threshold chosen to ensure adequate histological assessment. For this analysis,

we included 706 of the 991 patients from the primary study, excluding those with missing

covariates. The present study was designed to confirm that treatment effects (as measured by

the hazard ratio [HR], annual eGFR slope, and proteinuria ratio) derived from propensity

score-based weighting were consistent across outcomes, as shown in **Figure 1**. Moreover, we

checked the consistency between the HR observed in this study and HRs estimated from

existing meta-regression equations. Ethical approval was granted by The Jikei University

School of Medicine (approval no. 37-069 [12706]). All procedures conformed to the ethical

principles outlined in the Declaration of Helsinki and adhered to the STROBE reporting

standards.

Data Acquisition and Definitions

Demographic and clinical parameters, including age, sex, mean arterial pressure (MAP),

serum creatinine, estimated glomerular filtration rate (eGFR), serum uric acid, 24-hour

urinary proteinuria excretion (the urinary protein-to-creatinine ratio [UPCR] was permitted in

place of 24-hour urinary protein excretion at all time points except baseline), and urinary red

blood cell count, were systematically recorded at baseline and at 6-month intervals thereafter.

eGFR was determined using Uemura's equation [17] for participants under 20 years and

Matsuo's formula [18] for those aged 20 years and older. Histopathological assessment was

based on the Oxford MEST-C classification criteria [19, 20]. Therapeutic interventions administered within 12 months of biopsy, including corticosteroids, renin-angiotensin-aldosterone system (RAAS) inhibitors, and tonsillectomy, were documented.

Exposure Definition and Propensity Score-based Weighting Approach

Participants were stratified according to corticosteroid therapy initiation within one year following biopsy. To address baseline imbalances between treatment and non-treatment groups, propensity scores were calculated using logistic analysis including treatment as a dependent variable based on baseline covariates as independent variables, and overlap weighting was applied. Each participant was weighted by the probability of belonging to the opposite treatment group, emphasizing individuals with substantial covariate overlap.

Endpoints

For kidney outcomes, the primary endpoint was a composite of 40% or greater decline in eGFR from baseline based on two consecutive measurements or initiation of kidney replacement therapy. Secondary outcomes included (i) the 2-year eGFR slope, calculated from all available eGFR values from baseline to 2 years using a linear mixed model for repeated measures, and (ii) proteinuria reduction assessed using the proteinuria ratio at 1 year, defined as 1-year over baseline proteinuria.

Hazard Ratio and eGFR Slope Estimated from Meta-regression

To estimate the expected treatment effects on kidney outcomes, previously published meta-regression models were applied to the observed changes in surrogate markers.

The observed treatment effect on annual eGFR slope was substituted into two

different meta-regression equations that relate eGFR slope to the hazard ratio (HR) for kidney

outcomes. The first equation was derived from randomized controlled trials in IgAN, where

eGFR slope was calculated over a 1-year period [9]. The second equation was developed

from trials in broader CKD populations, using slopes calculated over at least 2 years [15].

The latter was included to reflect current methodological recommendations for slope-based

analyses, which favor longer follow-up to ensure stable estimates.

The effect of corticosteroid treatment on the proteinuria ratio was entered into a

separate meta-regression equation—derived from IgA nephropathy trials—that links the

degree of proteinuria reduction to the HR for kidney outcomes [9]. This model was used to

estimate the expected HR based solely on the proteinuria-lowering effect of treatment.

In addition, the observed proteinuria ratio was substituted into a meta-regression

equation to estimate eGFR slope [14]. This allowed indirect estimation of slope effects when

proteinuria was used as the primary marker of treatment response.

All estimated values from these models were then visually compared to the observed

values in the current study using forest plots.

Statistical Analyses

Descriptive statistics were applied to summarize baseline characteristics, expressed as mean

(standard deviation), median [interquartile range], or frequencies and percentages, as

appropriate. Weighted standardized differences were calculated to assess balance between

groups. Cox proportional hazards models were fitted using overlap weights based on

propensity scores, and baseline survival functions were subsequently estimated to generate

weighted survival curves based on corticosteroid treatments. Cox proportional hazards

models incorporating overlap weights were also used to estimate HRs with 95% confidence

intervals. Differences in annual eGFR slopes according to corticosteroid exposure were

evaluated using a linear mixed-effects model for repeated measures with random intercepts

and slopes, incorporating all available eGFR measurements from the first two years.

Differences in the log-transformed proteinuria ratio between corticosteroid groups were

assessed using a linear regression model. A two-sided P-value less than 0.05 was considered

statistically significant. Statistical analyses were performed using SAS version 9.4 (SAS

Institute Inc., Cary, NC, USA).

Results

Baseline Characteristics

Of the 991 patients in the primary study, a total of 706 patients with biopsy-confirmed IgAN

and no missing covariates were included in the present analysis. Among them, 359 patients

(50.8%) received corticosteroid therapy within 12 months of diagnosis. Before weighting,

patients receiving corticosteroids had higher proteinuria levels and lower baseline eGFR

compared to those not receiving corticosteroids. After applying overlap weighting, the

baseline characteristics were well-balanced between the two groups, with weighted

standardized differences of less than 0.001 for all covariates (**Table 1**).

Kidney Outcomes

During a median follow-up of 6.5 years, 147 patients (20.8%) developed the composite

kidney endpoint. The risk of the primary endpoint was significantly lower in the

corticosteroid group compared to the non-corticosteroid group (15.5% vs. 28.2%).

Overlap-weighted Cox proportional hazards analysis demonstrated that corticosteroid

exposure was associated with a significantly reduced risk of the composite endpoint

(weighted HR: 0.405; 95% CI: 0.211–0.777; P = 0.007) (**Figure 2**).

eGFR Slope

The mean eGFR decline over two years was significantly attenuated in patients receiving

corticosteroids compared to those not receiving them (–0.30 vs. –2.99 mL/min/1.73 m^2/year),

corresponding to a between-group difference of +2.69 mL/min/1.73 m²/year (95%CI:

+1.17–+4.21) (P = 0.01; **Figure 3**).

Proteinuria Ratio

Patients treated with corticosteroids showed a significantly greater reduction in proteinuria ratio at 1 year compared to those not receiving corticosteroids (0.521 vs 0.235) with a geometric mean difference of 0.452 (95%CI: 0.344–0.594) (P <0.001; **Figure 4**).

Comparison with Meta-Regression Estimations

To evaluate the validity of eGFR slope and proteinuria ratio as surrogate endpoints, we compared the actual observed effects of corticosteroid therapy on long-term kidney outcomes with the estimations derived from established meta-regression models. These models quantitatively link changes in surrogate markers to the risk of kidney disease progression based on aggregated data from multiple clinical trials. Specifically, the degree of proteinuria ratio and the improvement in the eGFR slope observed among corticosteroid-treated patients aligned closely with the magnitude of clinical benefit estimated by these models (**Figure 5**). The observed hazard reduction for the composite kidney outcome fell within the confidence intervals projected based on the changes in surrogate endpoints.

Discussion

In this post hoc analysis of a large-scale, prospective cohort of patients with biopsy-confirmed IgAN, we specifically focused on the evaluation of corticosteroid therapy as a key therapeutic intervention. By categorizing patients based on corticosteroid exposure and applying overlap weighting to achieve balance in baseline characteristics, we effectively minimized confounding by indication and approximated the conditions of a randomized controlled trial within a real-world setting. Our primary objective was to assess whether improvements in eGFR slope and proteinuria ratio, as surrogate markers, reliably reflected the clinical benefits of corticosteroid therapy. Importantly, the magnitude of the effects of treatment on both surrogate endpoints corresponded closely with the estimations derived from established meta-regression models. This consistency supports the validity of these markers as surrogate endpoints in the context of corticosteroid-induced therapeutic effects and underscores their utility for monitoring treatment response in clinical trials for IgAN.

Corticosteroid therapy is globally recognized for its efficacy in clinical trials and has long served as a cornerstone in the management of IgAN [10, 21]. In Japan, it has become firmly established as a standard treatment [12]. By focusing on this well-established intervention, our study provides critical clinically relevant insights into the utility of eGFR slope and proteinuria reduction as surrogate endpoints. Moreover, this approach enhances the translational impact of our study, as it reflects real-world treatment paradigms currently used in routine nephrology practice [22]. Our findings thus provide valuable insights into how surrogate markers perform not only in theoretical models but also in the context of established therapeutic strategies for IgAN.

Collectively, the present results reinforce the idea that early surrogate markers have clinical relevance in IgAN. Consistent with prior studies across various CKDs, including IgAN [9, 15], we found there that attenuation of eGFR decline and reductions in proteinuria

[13, 14, 23] were associated with improved long-term kidney prognosis in patients with IgAN.

Notably, the meta-regression models used for comparison were derived from aggregated data

encompassing a wide range of therapeutic interventions, not limited to any specific treatment

class. The consistency between the observed treatment effects of corticosteroid therapy and

the model-based expectations thus suggests that improvements in these surrogate markers are

reliably associated with clinical outcomes irrespective of the specific therapeutic strategy.

This finding further supports the validity of eGFR slope and proteinuria ratio as surrogate

endpoints in IgAN, indicating that monitoring these parameters can meaningfully capture

long-term therapeutic benefits across diverse treatment settings, including routine clinical

practice. Together, these methodological strengths contribute to the rigor of our study and

enhance confidence in the applicability of our findings to both clinical trial design and

real-world clinical practice.

Some limitations should be acknowledged. This was a post hoc, observational

analysis and residual confounding cannot be fully excluded despite rigorous adjustment.

Although corticosteroid therapy was standardized to some extent, variations in dosing

regimens, duration, and concurrent supportive treatments across institutions may have

influenced treatment responses. In addition, the use of real-world clinical data, while

enhancing generalizability, may have introduced variability in treatment protocols and

outcome measurements. Finally, the generalizability of our findings to other ethnic groups

remains to be confirmed, as the cohort was predominantly Japanese.

In conclusion, our study provides compelling evidence supporting the validity of

eGFR slope and proteinuria ratio as surrogate endpoints for kidney outcomes in patients with

IgAN receiving corticosteroid therapy. These markers may serve not only to facilitate

endpoint evaluation in clinical trials but also to enhance risk stratification and therapeutic

monitoring in routine nephrology practice.

References

1. D'Amico, G., *Natural history of idiopathic IgA nephropathy and factors predictive of disease outcome.* Semin Nephrol, 2004. **24**(3): p. 179-96.
2. Koyama, A., M. Igarashi, and M. Kobayashi, *Natural history and risk factors for immunoglobulin A nephropathy in Japan. Research Group on Progressive Renal Diseases.* Am J Kidney Dis, 1997. **29**(4): p. 526-32.
3. Bartosik, L.P., et al., *Predicting progression in IgA nephropathy.* Am J Kidney Dis, 2001. **38**(4): p. 728-35.
4. Moriyama, T., et al., *Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan.* PLoS One, 2014. **9**(3): p. e91756.
5. Shen, X., et al., *Long-term outcomes of IgA nephropathy in China.* Nephrol Dial Transplant, 2024.
6. Reich, H.N., et al., *Remission of proteinuria improves prognosis in IgA nephropathy.* J Am Soc Nephrol, 2007. **18**(12): p. 3177-83.
7. Thompson, A., et al., *Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.* Clin J Am Soc Nephrol, 2019. **14**(3): p. 469-481.
8. Barratt, J., et al., *eGFR slope modelling predicts long-term clinical benefit with nefecon in a real-world IgAN population.* Clin Kidney J, 2025. **18**(2): p. sfae404.
9. Lafayette, R.A., et al., *One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy.* Kidney Int Rep, 2022. **7**(12): p. 2730-2733.
10. Lv, J., et al., *Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.* Jama, 2022. **327**(19): p. 1888-1898.
11. Zhang, Z., et al., *Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials.* BMC Nephrol, 2019. **20**(1): p. 333.
12. Kawamura, T., et al., *Associations of corticosteroid therapy and tonsillectomy with kidney survival in a multicenter prospective study for IgA nephropathy.* Sci Rep, 2023. **13**(1): p. 18455.
13. Inker, L.A., et al., *Early Change in Urine Protein as a Surrogate End Point in Studies of IgA Nephropathy: An Individual-Patient Meta-analysis.* Am J Kidney Dis, 2016. **68**(3): p. 392-401.
14. Inker, L.A., et al., *Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.* Am J Kidney Dis, 2021. **78**(3): p. 340-349 e1.
15. Inker, L.A., et al., *GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials.* J Am Soc Nephrol, 2019. **30**(9): p. 1735-1745.
16. Koike, K., et al., *Clinicopathological prognostic stratification for proteinuria and kidney survival in IgA nephropathy: a Japanese prospective cohort study.* Clin Kidney J, 2024. **17**(1): p. sfad294.
17. Uemura, O., et al., *Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease.* Clin Exp Nephrol, 2014. **18**(4): p. 626-33.
18. Matsuo, S., et al., *Revised equations for estimated GFR from serum creatinine in Japan.* Am J Kidney Dis, 2009. **53**(6): p. 982-92.

19. Trimarchi, H., et al., *Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group.* Kidney Int, 2017. **91**(5): p. 1014-1021.

20. Haas, M., et al., *A Multicenter Study of the Predictive Value of Crescents in IgA Nephropathy.* J Am Soc Nephrol, 2017. **28**(2): p. 691-701.

21. Rauen, T., et al., *Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.* N Engl J Med, 2015. **373**(23): p. 2225-36.

22. Rovin, B.H., et al., *Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.* Kidney Int, 2021. **100**(4): p. 753-779.

23. Inker, L.A., et al., *Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis.* Am J Kidney Dis, 2014. **64**(1): p. 74-85.

Authors' Contributions

Conceptualization: Takaya Sasaki, Nobuo Tsuboi, Takashi Yokoo, Yusuke Suzuki.

Data curation: Takaya Sasaki.

Formal analysis: Takaya Sasaki.

Funding acquisition: Yusuke Suzuki.

Investigation: Takaya Sasaki, Nobuo Tsuboi.

Methodology: Takaya Sasaki.

Project administration: Nobuo Tsuboi, Takashi Yokoo, Yusuke Suzuki.

Supervision: Takashi Yokoo, Yusuke Suzuki.

Visualization: Takaya Sasaki.

Writing – original draft: Takaya Sasaki, Nobuo Tsuboi.

Writing – review & editing: Kentaro Koike, Hiroyuki Ueda, Masahiro Okabe, Shinya Yokote,

Akihiro Shimizu, Keita Hirano, Tetsuya Kawamura, Takashi Yokoo, Yusuke Suzuki.

Funding

This study was partly supported by a Grant-in-Aid for Progressive Renal Diseases Research,

Research on Rare and Intractable Disease, from the Ministry of Health, Labour and Welfare

of Japan. This research was supported by the Japan Agency for Medical Research and

Development under grant JP19ek0109261.

Financial Disclosure

YS has received consulting fees from Otsuka Pharmaceutical (Visterra), Novartis, Chinook

Therapeutics, ARGENX, BioCryst, Alexion Pharmaceuticals, Renalys, Alpine, and George

Clinical.

YS has also received honoraria for lectures, presentations, manuscript writing, or educational

events from Kyowa Kirin, Novartis, Mitsubishi Tanabe, Otsuka Pharmaceutical, Daiichi

Sankyo, AstraZeneca, Boehringer Ingelheim, and Chinook Therapeutics.

Acknowledgments

This study was approved by the ethics review board of the Jikei University School of

Medicine (approval no. 37-069 [12706]).

Data availability statement

All data produced in the present study are available upon reasonable request to the authors.

Figure legends

Figure 1. Overview of the study design and analytical approach.

The following outcomes were calculated and compared between corticosteroid-treated and

-untreated groups, with overlap weighting used to balance baseline characteristics: the hazard

ratio (HR) for the composite kidney endpoint, defined as a ≥40% decline in estimated

glomerular filtration rate (eGFR) or initiation of kidney replacement therapy (KRT); the

annual eGFR slope over a 2-year period; and the proteinuria ratio at 1 year relative to

baseline. In addition, the values observed in this study were compared with estimates based

on meta-regression equations.

Figure 2. Weighted survival curves for the cumulative incidence of the composite kidney

endpoint based on corticosteroid exposure.

The composite endpoint was defined as ≥40% decline in estimated glomerular filtration rate

or initiation of kidney replacement therapy. Cox proportional hazards models were fitted

using overlap weighting, and baseline survival functions were subsequently estimated to

generate weighted survival curves, and also used to estimate the hazard ratio (HR) with 95%

confidence interval (CI).

Figure 3. Comparison of the annual estimated glomerular filtration rate (eGFR) slope

for 2 years between corticosteroid-treated and untreated groups after overlap weighting.

A linear mixed-effect model for repeated measures with weighting was incorporated to depict

the trajectory of eGFR over time.

Figure 4. Comparison of proteinuria ratio at 1-year between corticosteroid-treated and

-untreated groups after overlap weighting.

A linear regression model with weighting was used for comparison.

Figure 5. Observed versus estimated treatment effects based on meta-regression models

linking surrogate endpoints to long-term kidney outcomes.

(A) Observed hazard ratio (HR) and HR calculated from the estimated glomerular filtration

rate (eGFR) slope. (B) Actual HR and HR calculated from proteinuria ratio. (C) Actual eGFR

slope and eGFR estimated from proteinuria ratio.

Table 1. Baseline characteristics based on corticosteroid treatment before and after overlap weighting.

	Before weighting			After weighting		
	Corticosteroid treatment			Corticosteroid treatment		
	Without (n=230)	With (n=476)	|SMD|	Without (n=93.6)	With (n=93.6)	|SMD|
Basic information						
Age, year	44.4 (17.1)	37.1 (15.5)	0.45	41.6 (19.2)	41.6 (23.4)	<0.001
Male sex, %	49.6	52.1	0.05	50.6	50.6	<0.001
Weight, kg	59.4 (12.5)	58.8 (13.4)	0.05	59.2 (16.6)	59.2 (16.5)	<0.001
Height, cm	162.1 (9.8)	162.1 (11)	0.001	162.4 (10.9)	162.4 (11.8)	<0.001
Past medical history						
Diabetes mellitus, %	0.9	2.1	0.10	1.5	1.5	<0.001
Systolic blood pressure, mmHg	125.1 (18)	120.7 (16.9)	0.25	123.4 (21.5)	123.4 (25.3)	<0.001
Antihypertensive drug, %	43.5	37.4	0.12	39.0	39.0	<0.001
Statin, %	12.2	9.9	0.07	11.0	11.0	<0.001
Kidney-related measurements						
eGFR, mL/min/1.73 m^2	72.3 (27.9)	77.1 (28.4)	0.17	74.1 (32.9)	74.1 (36.6)	<0.001
UPE, g/day or g/g	0.8 (1.4)	1.4 (2.8)	0.26	0.9 (2.5)	0.9 (1.2)	<0.001
Microhematuria, %	99.6	99.6	0.002	99.6	99.6	<0.001
Histopathological findings						
M1, %	22.6	31.3	0.2	25.5	25.5	<0.001
E1, %	21.7	42.6	0.46	30.7	30.7	<0.001
S1, %	63.5	80.7	0.39	72.7	72.7	<0.001
T1 or 2, %	23.9	21.2	0.06	21.7	21.7	<0.001
C1 or 2, %	20.4	48.1	0.61	31.1	31.1	<0.001
Blood tests						
Sodium, mmol/L	140.4 (2.3)	140.3 (2.1)	0.09	140.2 (2.3)	140.2 (3.0)	<0.001
Potassium, mmol/L	4.2 (0.4)	4.2 (0.4)	0.02	4.2 (0.4)	4.2 (0.5)	<0.001
ALT, IU/L	19.0 (14.4)	17.7 (13.1)	0.10	18.0 (13.1)	18.0 (15.3)	<0.001
AST, IU/L	20.6 (12.3)	20.4 (10.2)	0.01	20.5 (20.7)	20.5 (12.0)	<0.001
Alb, g/dL	4.0 (0.4)	3.9 (0.6)	0.36	4.0 (0.6)	4.0 (0.6)	<0.001
Uric acid, mg/dL	5.9 (1.7)	5.8 (1.6)	0.09	5.9 (1.8)	5.9 (2.4)	<0.001
IgA, g/L	3.25 (1.20)	3.42 (1.27)	0.14	3.34 (1.68)	3.34 (1.77)	<0.001
Hb, g/dL	13.4 (1.7)	13.3 (1.7)	0.05	13.3 (1.9)	13.3 (2.4)	<0.001
WBC, /μL	6623 (5671)	6656 (1838)	0.01	6580 (2980)	6580 (2650)	<0.001
Initial treatment						
Tonsillectomy, %	13.0	59.2	1.10	25.9	25.9	<0.001
Immunosuppressive agent, %	1.3	7.4	0.30	1.9	1.9	<0.001
RAS inhibitor, %	68.3	56.5	0.24	62.0	62.0	<0.001

Figure 1

Figure 2

Figure 3

Figure 4

Figure 5